Leading healthcare company Johnson & Johnson (JNJ) performs well amid uncertain economic conditions, as evidenced by its core business segments’ continued strength and stability in 2022. The company’s robust financials, solid growth prospects, and reliable dividends make it a stable and dependable investment option that investors can hold for the long run. Let’s discuss this in detail.
Over the past years, the healthcare conglomerate JNJ demonstrated its ability to evolve continuously and adapt by spearheading Research and Development (R&D) efforts for COVID-19 vaccines and other medical treatments.
